Differences between Botox and Xeomin
Contents
Botox vs. Xeomin[edit]
Botox (onabotulinumtoxinA) and Xeomin (incobotulinumtoxinA) are injectable neuromodulators derived from the bacterium Clostridium botulinum. Both medications function by inhibiting the release of acetylcholine at the neuromuscular junction, which causes temporary muscle relaxation. Clinicians use these agents for aesthetic treatments, such as the reduction of glabellar lines, and therapeutic indications, including cervical dystonia and chronic migraine. While the active neurotoxin in both products is botulinum toxin type A, they differ in molecular composition, manufacturing processes, and storage requirements.[1]
Comparison table[edit]
| Category | Botox | Xeomin |
|---|---|---|
| Generic name | OnabotulinumtoxinA | IncobotulinumtoxinA |
| Manufacturer | Allergan (AbbVie) | Merz Pharmaceuticals |
| Accessory proteins | Included (900 kDa complex) | Removed (150 kDa "naked" toxin) |
| FDA cosmetic approval | 2002 | 2011 |
| Storage (unopened) | Refrigerated (2°C to 8°C) | Room temperature (up to 25°C) |
| Shelf life | 36 months (refrigerated) | 36 months (room temperature) |
| Onset of action | 3 to 7 days | 3 to 7 days |
| Typical duration | 3 to 4 months | 3 to 4 months |
Protein composition and purification[edit]
The primary structural difference between the two products is the presence of complexing proteins. Botox contains the 150 kDa botulinum toxin molecule surrounded by accessory proteins, resulting in a total molecular weight of approximately 900 kDa. Xeomin undergoes a purification process that removes these accessory proteins, leaving only the active 150 kDa neurotoxin. Merz Pharmaceuticals refers to this as a "naked" neurotoxin.[2]
The absence of complexing proteins may influence immunogenicity. Some clinical data suggests that the purification of Xeomin reduces the risk of a patient developing neutralizing antibodies. These antibodies can render botulinum treatments less effective or cause complete treatment resistance over time. However, the clinical significance of this difference remains a subject of ongoing research, as antibody formation is relatively rare for both products when used at standard cosmetic doses.[3]
Storage and stability[edit]
Storage protocols differ significantly due to the molecular stability of the formulations. Botox must be kept refrigerated or frozen from the point of manufacture until it is reconstituted for use. Deviations from the "cold chain" can lead to a loss of potency. Xeomin is stable at room temperature (up to 25°C or 77°F) for up to three years before the vial is opened. This stability simplifies shipping logistics and reduces the risk of product degradation in clinical settings where refrigeration may be inconsistent. After reconstitution with preservative-free saline, both medications typically require refrigeration and should be administered within 24 hours.
Clinical efficacy and dosing[edit]
Most clinical trials indicate a 1:1 dose conversion ratio between Botox and Xeomin. Patients receiving 20 units of Botox for frown lines generally require 20 units of Xeomin to achieve equivalent muscle relaxation. Studies comparing the two products for the treatment of blepharospasm and glabellar lines have shown no statistically significant difference in the speed of onset or the duration of effect. Most patients observe the start of muscle weakening within one week, with peak results occurring at 14 days and lasting between three and four months.
References[edit]
- ↑ Dressler, D. (2012). "Five years' experience with incobotulinumtoxinA (Xeomin): the first protein-free botulinum toxin type A preparation." Neuropsychiatric Disease and Treatment, 8, 113–118.
- ↑ Kerscher, M., et al. (2012). "Incipient antibody formation to onabotulinumtoxinA and incobotulinumtoxinA." Dermatologic Surgery, 38(7 Pt 2), 1181-1188.
- ↑ Park, J. Y., et al. (2020). "Immunogenicity associated with botulinum toxin treatment." Toxins, 12(1), 32.
